Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that competition negatively impacted the demand for the Lapiplasty system, leading to a decline in Treace Medical's revenue [3]. - The company needed to accelerate plans for an alternative product to osteotomy due to these challenges [3]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading [3]. Next Steps for Shareholders - Shareholders who purchased TMCI shares during the specified period are encouraged to register for the class action by June 10, 2025 [4]. - Registration allows shareholders to receive updates through portfolio monitoring software [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Treace Medical between May 8, 2023, and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- ...

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities of the June 10, 2025 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the Class Period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [5] - The lawsuit asserts that the positive statements made by Treace Medical about its business and prospects were materially misleading and lacked a reasonable basis [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [4]

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities from May 8, 2023, to May 7, 2024, about the June 10, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by June 10, 2025 [3] Group 2 - The lawsuit alleges that during the class period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5] - The lawsuit claims that Treace Medical needed to accelerate plans for an alternative product to osteotomy due to the impact of competition [5] - Defendants' positive statements about Treace Medical's business and prospects were materially misleading and lacked a reasonable basis, resulting in investor damages when the truth was revealed [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4] - The firm has been recognized for its performance in securities class action settlements, including a record settlement against a Chinese company and ranking highly in the number of settlements achieved [4]

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) (“Treace Medical” or the “Company”) securities between May 8, 2023 and May 7, 2024 (the “Class Period”), charging the Company and certain senior executives with violations of the federal securities laws (collectively, “Defendants”). Treace Medical investors have until June 10, 2025 to seek appointment as le ...

NEW YORK, April 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TMCI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 10, 2025. There is no cost or obligation to you to ...

Core Viewpoint - A class action has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical failed to disclose competition's impact on the demand for its primary product, resulting in a revenue decline [2]. - Following the revelation of these facts, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 10, 2025 [3]. - Shareholders can choose to remain absent class members without participating in the case [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [3]. - Defendants allegedly made positive statements about the company's business and prospects that were materially misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors who purchased Treace Medical securities during the Class Period can request to be appointed as Lead Plaintiff by June 10, 2025 [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance reduction, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action securities lawsuit due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," was negatively affected by competition, leading to a decline in revenue [2] - As a result of the revenue decline, Treace Medical needed to expedite plans for an alternative product to osteotomy [2] - The defendants allegedly made misleading positive statements regarding the company's business and prospects, which lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]